Cargando…

Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report

BACKGROUND: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor immune response by targeting programmed cell death 1 receptor. The use of pembrolizumab plus carboplatin/pemetrexed combination therapy results in improvement in overall survival and progression-free s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fakhri, Ghina, Akel, Reem, Salem, Ziad, Tawil, Ayman, Tfayli, Arafat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836160/ https://www.ncbi.nlm.nih.gov/pubmed/29515398 http://dx.doi.org/10.1159/000484596

Ejemplares similares

Burnout among Lebanese Oncologists: Prevalence and Risk Factors
por: Salem, Rana, et al.
Publicado: (2018)

Paraneoplastic Pemphigus as a First Manifestation of an Intra-Abdominal Follicular Dendritic Cell Sarcoma: Rare Case and Review of the Literature
por: Akel, Reem, et al.
Publicado: (2018)

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon
por: Fakhri, Ghina, et al.
Publicado: (2021)

Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon
por: Fakhri, Ghina B., et al.
Publicado: (2018)

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
por: Tfayli, Arafat, et al.
Publicado: (2020)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report
por: Akel, Reem, et al.
Publicado: (2017)

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region
por: Tfayli, Arafat Hussein, et al.
Publicado: (2019)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Sarcoidosis‐like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response
por: Shi, Yuequan, et al.
Publicado: (2021)

Prevalence and Correlates of Complementary and Alternative Medicine Use among Patients with Lung Cancer: A Cross-Sectional Study in Beirut, Lebanon
por: Naja, Farah, et al.
Publicado: (2017)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

Cancer-Related Pain: Prevalence, Severity and Management in a Tertiary Care Center in the Middle East
por: Hamieh, Nadine M, et al.
Publicado: (2018)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg, Frank, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
por: Zhang, Xin, et al.
Publicado: (2023)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
por: Weiss, Glen J, et al.
Publicado: (2017)

Anxiety, Depression and Quality of Life in Breast Cancer Patients in the Levant
por: Akel, Reem, et al.
Publicado: (2017)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
por: Satake, Hironaga, et al.
Publicado: (2022)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
por: Guo, Yimeng, et al.
Publicado: (2023)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
por: Zhao, Guangyin, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab
por: Lise, Qu-Knafo, et al.
Publicado: (2016)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fvcs5idb4rqtjguo100di4lue0